Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with BioNTech signals management's ambition to revitalize growth and address long-term potential in oncology. Despite near-term 'dead money' concerns, BMY's deeply discounted valuation, while paying more than 5% in dividend yield offers an attractive margin of safety.
5 of the Safest Strong-Buy High-Yield Dividend Stocks Are On Sale Now
Investors love dividend stocks, especially high-yield ones, because they offer a significant income stream and have substantial total return potential.
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July.
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bargain Alert: I'm Buying Monthly Dividends Up To 7% Yield
Timing of income is an important consideration. Monthly dividend stocks provide recurring income and faster compounding of wealth. I highlight two monthly dividend payers that are undervalued while supporting well-covered yields. Both carry strong balance sheets with A- and BBB+ credit ratings and durable business models that support growth for years to come.
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
BMY Reports Positive Data on Sotyktu From Arthritis Study
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royaltie
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
